Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Valued as a pre-revenue company: Net cash floor and Analyst consensus.
ACCE opinion60 Degrees Pharmaceuticals Inc. Common Stock (SXTP)
Fair value
Not available
ACCE price target
$0.37
Rating
Not rated
Horizon
12 months
ACCE price target published on 15 Oct 2026, 00:00 CEST.
Price used: $0.87 at the close on 23 Oct 2026, 22:00 CEST.
Models: Analyst consensus and Net cash floor.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
20
out of 100
Analysts
50% buy
2 covering
P/E
0.0x
forward 0.0x
1-year return
-85.0%
Dividend yield
0.00%
60 Degrees Pharmaceuticals Inc. Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
60 Degrees Pharmaceuticals sells Arakoda, an oral tafenoquine tablet for malaria prophylaxis, plus a small line of tafenoquine-based products sourced for travelers and military use. The bull case rests on a narrow regulatory and distribution moat: tafenoquine is a differentiated antimalarial, and the company holds the commercial rights in the U.S. and several other markets. The data we have does not show that moat turning into revenue, though. Revenue is shrinking 32.5% year over year, gross margin is negative 169.9%, and operating margin is negative 1,092.4%, meaning each dollar of sales is currently costing the company well over ten dollars to produce and sell. Return on equity of negative 332.9% and a $3M market cap put this firmly in micro-cap distress territory, with a composite score of 20/100 and no index membership. Unless a near-term catalyst can be identified that reverses the sales trend and gross margin, this is a name to screen out rather than research further.
⚠ Investor warnings · 3 flagsAI-assisted·How I use AI
severe
Negative gross margin
Gross margin is -169.9% and operating margin is -1092.4%, so the company loses money on each unit sold before overhead. Free cash flow was $-7.07M against a $3M market cap.
high
Revenue collapsing
Revenue fell 32.5% year over year, 14.4% compounded over five years, and 46.6% quarter over quarter. Operating losses continue at this scale.
high
Price above model fair value
Price is $0.88 against an ACCE fair value of $0.37 (range $0.19-$0.90), so the stock sits at the top of the model range.
AI research notes
AI-assisted·How I use AIWritten Oct 15, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
Analysts' mean price target sits well above the current share price, pointing to meaningful upside on paper.
Half of covering analysts rate the stock Buy or Strong Buy, a sign that some professional support remains.
Debt is minimal relative to equity, so the balance sheet carries little borrowing pressure.
Why it could disappoint
Revenue fell 32.5% over the past year and has shrunk by an average of 14.4% a year over five years.
Free cash flow was negative $7M over the last twelve months, so the business is burning cash rather than generating it.
The diluted share count rose 489.6% last fiscal year, heavily diluting existing holders' stakes.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Next results
Nov 12, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where SXTP's valuation models land
Price
$0.87
Model fair valueConfidence: low
about $2.09
Model
Fair value
Upside
Analyst consensus
Net cash floor
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores